Camaro1093 Stocks!

[TH_Stockhunter]

Actually its sunday the 24th, but still...

Here is a nice post about the future events that could have positive effect on PARD share price:


Posted by: elcheepo Date: Thursday, January 21, 2010 12:58:49AM
In reply to: $heff who wrote msg# 22428 Post # of 22471

PARD is shown to be presenting;

http://www.ceo.bio.org/opencms/ceo/2010/Companies/PresentingCompanies.html

Points on PARD to consider;
1) PARD will present additional data from their Phase 2 trial using picoplatin in colorectal cancer (CRC) l on January 24.

2) PARD will present data from their Phase 2 trial using picoplatin in prostate cancer on March 5th.

3) A massive short covering rally (with a current 20% - 25% short interest) caused by upward momentum from investors.

4) Talks with the FDA for a path forward for picoplatin in small cell lung cancer (SCLC) in the first half of this year.

5) More updates from trial of an oral formulation of picoplatin, which were presented in 2009, may also occur during this time.

6) PARD fundamentals: Picoplatin avoids many of the toxicities of the widely used platinum drugs, which represent an almost $4 billion market in the US. PARD currently has about $40 million in cash to continue to develop picoplatin and break into this large market.

7) Technical rally: Technical indicators show that PARD is oversold (probably due to its massive short position), with a strong trend of accumulation and a return to positive moving averages.

With data from approximately 1,100 patients treated with picoplatin in lung, colorectal, prostate and ovarian cancers, there is a lot of data available to gauge the likelihood of its success in clinical trials. If approved, picoplatin could be substituted for platinum-based therapies which is the current standard of care (SOC) in numerous indications. However, currently available platinum therapies have significant shortcomings, including toxicities and drug resistance (both intrinsic and acquired) that limit their use. Picoplatin has several potential benefits over existing platinum therapy.